G20210A prothrombin gene variant and clinical outcome in patients with a first acute coronary syndrome

Francesco Burzotta, Antonio Maria Leone, Katia Paciaroni, Valerio De Stefano, Elena Rossi, Luca Testa, Floriana Giannico, Giuseppe Leone, Attilio Maseri, Filippo Crea, Felicita Andreotti

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background and Objectives. The prognostic value of the G20210A prothrombin gene polymorphism in patients with a first acute coronary syndrome has not been previously assessed. We conducted a prospective study to investigate this issue. Design and Methods. Genotyping at the 20210 prothrombin gene locus was performed in 162 patients with a first episode of myocardial infarction (MI) or unstable angina (UA) occurring before 65 years of age. Patients were stratified according to cardiovascular risk factors and to treatment strategy. The subsequent two-year relative risk (RR) of adverse events (death, MI and UA) was adjusted for possible confounders and analyzed according to genotype, risk factor category, and treatment allocation. Results. In the entire study population, the prothrombin variant did not significantly increase the two-year risk of events: the adjusted RR for GA vs GG carriers was 1.82 (95% CI 0.68-4.89). However, in the absence of traditional cardiovascular risk factors the risk of events was consistently higher: among the 46 patients without hypertension, diabetes and hypercholesterolemia, GA vs GG carriership was associated with an adjusted RR at two years of 5.64 (95% CI 1.07-29.84). The gene variant also enhanced the risk of events among the 98 patients who did not undergo myocardial revascularization procedures (RR for GA vs GG: 2.89, 95% CI 1.04-8.00), but not among those who did. Interpretation and Conclusions. The present prospective study suggests that heterozygosity for the G20210A prothrombin polymorphism adversely affects prognosis after a first acute coronary syndrome in the subgroup of patients without metabolic risk factors and in those not treated by revascularization procedures.

Original languageEnglish
Pages (from-to)1134-1138
Number of pages5
JournalHaematologica
Volume89
Issue number9
Publication statusPublished - Sep 2004

Fingerprint

Prothrombin
Acute Coronary Syndrome
Genes
Unstable Angina
Myocardial Infarction
Prospective Studies
Myocardial Revascularization
Hypercholesterolemia
Genotype
Hypertension
Therapeutics
Population

Keywords

  • Acute coronary syndromes
  • Cardiovascular risk factors
  • Gene polymorphism
  • Myocardial revascularization
  • Outcome
  • Prothrombin

ASJC Scopus subject areas

  • Hematology

Cite this

Burzotta, F., Leone, A. M., Paciaroni, K., De Stefano, V., Rossi, E., Testa, L., ... Andreotti, F. (2004). G20210A prothrombin gene variant and clinical outcome in patients with a first acute coronary syndrome. Haematologica, 89(9), 1134-1138.

G20210A prothrombin gene variant and clinical outcome in patients with a first acute coronary syndrome. / Burzotta, Francesco; Leone, Antonio Maria; Paciaroni, Katia; De Stefano, Valerio; Rossi, Elena; Testa, Luca; Giannico, Floriana; Leone, Giuseppe; Maseri, Attilio; Crea, Filippo; Andreotti, Felicita.

In: Haematologica, Vol. 89, No. 9, 09.2004, p. 1134-1138.

Research output: Contribution to journalArticle

Burzotta, F, Leone, AM, Paciaroni, K, De Stefano, V, Rossi, E, Testa, L, Giannico, F, Leone, G, Maseri, A, Crea, F & Andreotti, F 2004, 'G20210A prothrombin gene variant and clinical outcome in patients with a first acute coronary syndrome', Haematologica, vol. 89, no. 9, pp. 1134-1138.
Burzotta F, Leone AM, Paciaroni K, De Stefano V, Rossi E, Testa L et al. G20210A prothrombin gene variant and clinical outcome in patients with a first acute coronary syndrome. Haematologica. 2004 Sep;89(9):1134-1138.
Burzotta, Francesco ; Leone, Antonio Maria ; Paciaroni, Katia ; De Stefano, Valerio ; Rossi, Elena ; Testa, Luca ; Giannico, Floriana ; Leone, Giuseppe ; Maseri, Attilio ; Crea, Filippo ; Andreotti, Felicita. / G20210A prothrombin gene variant and clinical outcome in patients with a first acute coronary syndrome. In: Haematologica. 2004 ; Vol. 89, No. 9. pp. 1134-1138.
@article{8c4e42e3098641b9a0f988b64bd78962,
title = "G20210A prothrombin gene variant and clinical outcome in patients with a first acute coronary syndrome",
abstract = "Background and Objectives. The prognostic value of the G20210A prothrombin gene polymorphism in patients with a first acute coronary syndrome has not been previously assessed. We conducted a prospective study to investigate this issue. Design and Methods. Genotyping at the 20210 prothrombin gene locus was performed in 162 patients with a first episode of myocardial infarction (MI) or unstable angina (UA) occurring before 65 years of age. Patients were stratified according to cardiovascular risk factors and to treatment strategy. The subsequent two-year relative risk (RR) of adverse events (death, MI and UA) was adjusted for possible confounders and analyzed according to genotype, risk factor category, and treatment allocation. Results. In the entire study population, the prothrombin variant did not significantly increase the two-year risk of events: the adjusted RR for GA vs GG carriers was 1.82 (95{\%} CI 0.68-4.89). However, in the absence of traditional cardiovascular risk factors the risk of events was consistently higher: among the 46 patients without hypertension, diabetes and hypercholesterolemia, GA vs GG carriership was associated with an adjusted RR at two years of 5.64 (95{\%} CI 1.07-29.84). The gene variant also enhanced the risk of events among the 98 patients who did not undergo myocardial revascularization procedures (RR for GA vs GG: 2.89, 95{\%} CI 1.04-8.00), but not among those who did. Interpretation and Conclusions. The present prospective study suggests that heterozygosity for the G20210A prothrombin polymorphism adversely affects prognosis after a first acute coronary syndrome in the subgroup of patients without metabolic risk factors and in those not treated by revascularization procedures.",
keywords = "Acute coronary syndromes, Cardiovascular risk factors, Gene polymorphism, Myocardial revascularization, Outcome, Prothrombin",
author = "Francesco Burzotta and Leone, {Antonio Maria} and Katia Paciaroni and {De Stefano}, Valerio and Elena Rossi and Luca Testa and Floriana Giannico and Giuseppe Leone and Attilio Maseri and Filippo Crea and Felicita Andreotti",
year = "2004",
month = "9",
language = "English",
volume = "89",
pages = "1134--1138",
journal = "Haematologica",
issn = "0390-6078",
publisher = "NLM (Medline)",
number = "9",

}

TY - JOUR

T1 - G20210A prothrombin gene variant and clinical outcome in patients with a first acute coronary syndrome

AU - Burzotta, Francesco

AU - Leone, Antonio Maria

AU - Paciaroni, Katia

AU - De Stefano, Valerio

AU - Rossi, Elena

AU - Testa, Luca

AU - Giannico, Floriana

AU - Leone, Giuseppe

AU - Maseri, Attilio

AU - Crea, Filippo

AU - Andreotti, Felicita

PY - 2004/9

Y1 - 2004/9

N2 - Background and Objectives. The prognostic value of the G20210A prothrombin gene polymorphism in patients with a first acute coronary syndrome has not been previously assessed. We conducted a prospective study to investigate this issue. Design and Methods. Genotyping at the 20210 prothrombin gene locus was performed in 162 patients with a first episode of myocardial infarction (MI) or unstable angina (UA) occurring before 65 years of age. Patients were stratified according to cardiovascular risk factors and to treatment strategy. The subsequent two-year relative risk (RR) of adverse events (death, MI and UA) was adjusted for possible confounders and analyzed according to genotype, risk factor category, and treatment allocation. Results. In the entire study population, the prothrombin variant did not significantly increase the two-year risk of events: the adjusted RR for GA vs GG carriers was 1.82 (95% CI 0.68-4.89). However, in the absence of traditional cardiovascular risk factors the risk of events was consistently higher: among the 46 patients without hypertension, diabetes and hypercholesterolemia, GA vs GG carriership was associated with an adjusted RR at two years of 5.64 (95% CI 1.07-29.84). The gene variant also enhanced the risk of events among the 98 patients who did not undergo myocardial revascularization procedures (RR for GA vs GG: 2.89, 95% CI 1.04-8.00), but not among those who did. Interpretation and Conclusions. The present prospective study suggests that heterozygosity for the G20210A prothrombin polymorphism adversely affects prognosis after a first acute coronary syndrome in the subgroup of patients without metabolic risk factors and in those not treated by revascularization procedures.

AB - Background and Objectives. The prognostic value of the G20210A prothrombin gene polymorphism in patients with a first acute coronary syndrome has not been previously assessed. We conducted a prospective study to investigate this issue. Design and Methods. Genotyping at the 20210 prothrombin gene locus was performed in 162 patients with a first episode of myocardial infarction (MI) or unstable angina (UA) occurring before 65 years of age. Patients were stratified according to cardiovascular risk factors and to treatment strategy. The subsequent two-year relative risk (RR) of adverse events (death, MI and UA) was adjusted for possible confounders and analyzed according to genotype, risk factor category, and treatment allocation. Results. In the entire study population, the prothrombin variant did not significantly increase the two-year risk of events: the adjusted RR for GA vs GG carriers was 1.82 (95% CI 0.68-4.89). However, in the absence of traditional cardiovascular risk factors the risk of events was consistently higher: among the 46 patients without hypertension, diabetes and hypercholesterolemia, GA vs GG carriership was associated with an adjusted RR at two years of 5.64 (95% CI 1.07-29.84). The gene variant also enhanced the risk of events among the 98 patients who did not undergo myocardial revascularization procedures (RR for GA vs GG: 2.89, 95% CI 1.04-8.00), but not among those who did. Interpretation and Conclusions. The present prospective study suggests that heterozygosity for the G20210A prothrombin polymorphism adversely affects prognosis after a first acute coronary syndrome in the subgroup of patients without metabolic risk factors and in those not treated by revascularization procedures.

KW - Acute coronary syndromes

KW - Cardiovascular risk factors

KW - Gene polymorphism

KW - Myocardial revascularization

KW - Outcome

KW - Prothrombin

UR - http://www.scopus.com/inward/record.url?scp=4644297607&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4644297607&partnerID=8YFLogxK

M3 - Article

C2 - 15377476

AN - SCOPUS:4644297607

VL - 89

SP - 1134

EP - 1138

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 9

ER -